Why hasn’t FDA banned kratom?
FDA lacks direct authority to unilaterally “ban” supplements; it can issue import alerts, warning letters, and mandatory recalls. However, FDA repeatedly states kratom is not lawfully marketed and has no approved uses. Scheduling requires DEA action or legislation.
What is 7‑OH?
7‑hydroxymitragynine is a potent oxidized alkaloid found in trace amounts in natural kratom but can be concentrated or synthetically boosted. It has opioid‑like effects with higher abuse potential and has been linked to deaths and severe withdrawal.
Are poison‑center reports increasing?
Yes. CDC MMWR (2026) documented a 1,200% rise from 2015 to 2025. 2025 saw a spike concurrent with high‑potency 7‑OH products entering the market.
Are severe outcomes documented?
Yes. Systematic reviews and case series report seizures, cardiac arrest, Brugada pattern, liver failure, ICU admissions, and deaths. Single‑substance fatalities have been certified by medical examiners.
Are children being exposed?
America’s Poison Centers data show pediatric exposures increasing; children under 5 represent the largest pediatric group. Adolescent intentional exposures also occur.
What authority do states have?
States can schedule kratom alkaloids via their controlled substance acts, restrict sales to adults, require registration, or ban products. Six states have scheduling or bans; others have KCPA (regulatory) statutes.
Why do some states schedule kratom?
Based on documented addiction, overdose deaths, neonatal abstinence, and contamination. Ohio, Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin have scheduling or full bans.
Can contamination occur in “natural leaf” products?
Yes. FDA recalls demonstrate Salmonella, Klebsiella, and heavy metals (lead, nickel) in raw leaf powder. “Natural” does not imply safe.
CDC MMWR: 1,200% increase in kratom poison center reports (2015-2025)
MMWR 2026;75(11):140-146
Read summaryFDA Import Alert 54-15: Detention of all kratom dietary supplements
FDA 2025
View alertKratom regulation study: States with bans had fewer severe outcomes
Addiction 2026; doi:10.1111/add.70416
Read studyFDA ICP-MS heavy metals analysis: Lead, nickel exceeding safe daily limits
FDA Laboratory Analysis 2019
Download dataNeonatal abstinence syndrome from prenatal kratom exposure
Pediatrics 2018; Neonatology review 2023
Read reviewCardiac toxicity: Brugada syndrome & ventricular fibrillation
JACC Case Rep. 2025-2026
See case seriesMultistate Salmonella outbreak linked to kratom (199 cases, 41 states)
J Food Prot. 2022
Outbreak reportSingle-drug fatalities with mitragynine as sole intoxicant
J Anal Toxicol. 2022; Acad Forensic Pathol 2023
Read cases
1,200%
Increase in poison center calls (2015-2025)
Exposure trend: steep rise 2019-2025
199
Salmonella outbreak cases
55% of FDA samples positive for Salmonella
32
Published liver injury cases
Cholestatic & hepatocellular injury
707
Pediatric exposures (2019-2024)
107 cases in 2024 alone
Policy Considerations: Retail Ban vs. Schedule I Placement
Retail Ban (State Level)
Prohibits the sale, distribution, or possession of kratom products for consumers. Enforced by state and local agencies.
- Removes products from gas stations, smoke shops, online retailers
- Reduces accessibility and normalisation
- Evidence from ban states shows lower exposure rates and severe outcomes (Addiction 2026)
- Requires robust enforcement and interstate coordination
Schedule I Placement (Federal)
Classifies mitragynine and 7‑OH as controlled substances with no accepted medical use and high abuse potential.
- Uniform federal prohibition, criminal penalties for manufacturing/distribution
- DEA enforcement, import controls, research restrictions
- Aligns with FDA findings of no approved medical use
- Addresses interstate commerce and online sales gaps
Comparative Considerations
Both approaches aim to reduce harm, but differ in scope and enforcement burden.
- Retail bans faster to implement at state level but patchwork coverage
- Schedule I provides nationwide uniformity but requires federal action
- Some states have adopted KCPA (regulation) but contamination and poison center calls persist
- Evidence suggests prohibition more effective than regulatory schemes in reducing severe medical outcomes
DEA Citizen Petition Under Review
A citizen petition requesting DEA to classify kratom (mitragynine and 7‑OH) as Schedule I controlled substances is currently under agency review. Final decision pending.
Monitor DEA →FDA Import Alert 54-15
Detention without physical examination of all kratom‑containing dietary supplements.
View document →FDA Mandatory Recall Order
Triangle Pharmataturals (2018) – first mandatory recall for Salmonella‑contaminated kratom.
Recall details →State Scheduling / Bans
Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin, and others have scheduled mitragynine or banned kratom.
Effectiveness study →KCPA States
Several states enacted Kratom Consumer Protection Acts (age 21+, labeling, testing). However, contamination and recalls persist under KCPA.
Read analysis →State Pharmacy Board Actions
Ohio Board of Pharmacy proposed Schedule I for mitragynine (2026).
Read proposal →
Why This Matters
Policymakers increasingly face questions involving public health, retail accessibility, product variability, overdose surveillance, and regulatory oversight related to kratom and emerging alkaloid products. This resource is intended to support evidence‑informed discussion and policy evaluation.
